Avanos Medical/$AVNS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Avanos Medical
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.
Ticker
$AVNS
Sector
Primary listing
NYSE
Employees
2,227
Headquarters
Website
Avanos Medical Metrics
BasicAdvanced
$546M
-
-$10.15
1.10
-
Price and volume
Market cap
$546M
Beta
1.1
52-week high
$19.48
52-week low
$9.30
Average daily volume
477K
Financial strength
Current ratio
2.376
Quick ratio
1.231
Long term debt to equity
14.756
Total debt to equity
17.185
Interest coverage (TTM)
2.24%
Profitability
EBITDA (TTM)
59.6
Gross margin (TTM)
52.28%
Net profit margin (TTM)
-67.00%
Operating margin (TTM)
4.91%
Effective tax rate (TTM)
3.96%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
1.58%
Return on equity (TTM)
-46.68%
Valuation
Price to revenue (TTM)
0.777
Price to book
0.7
Price to tangible book (TTM)
2.09
Price to free cash flow (TTM)
7.258
Free cash flow yield (TTM)
13.78%
Free cash flow per share (TTM)
1.62
Growth
Revenue change (TTM)
2.70%
Earnings per share change (TTM)
-3,078.59%
3-year revenue growth (CAGR)
0.19%
10-year revenue growth (CAGR)
-8.01%
3-year earnings per share growth (CAGR)
120.99%
10-year earnings per share growth (CAGR)
0.65%
What the Analysts think about Avanos Medical
Analyst ratings (Buy, Hold, Sell) for Avanos Medical stock.
Bulls say / Bears say
SNS segment net sales rose 16.1% YoY to $114.0 million in Q3 2025, driven by strong demand for enteral feeding and neonate solutions (Zacks).
Avanos completed the acquisition of Nexus Medical in September 2025, adding complementary neonatal and pediatric intensive-care technology expected to enhance its Specialty Nutrition Systems offerings (TipRanks).
Management raised and narrowed its 2025 revenue guidance to $690 million–$700 million and adjusted EPS guidance to $0.85–$0.95, signaling confidence in sustaining momentum in core segments (TipRanks).
Avanos reported a net loss of $1.4 million (–$0.03 per share) in Q3 2025, compared to a net income of $5.9 million a year earlier, highlighting continued profitability challenges (TipRanks).
The company recorded a $77.0 million goodwill impairment charge in its Pain Management & Recovery segment in Q2 2025, underscoring valuation pressures in that business line (AInvest).
AVNS shares have fallen 33.1% year-to-date through November 5, 2025, versus a 0.1% decline for the industry, reflecting investor concerns over the company’s near-term outlook (Finviz).
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2025.
Avanos Medical Financial Performance
Revenues and expenses
Avanos Medical Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Avanos Medical stock?
Avanos Medical (AVNS) has a market cap of $546M as of November 13, 2025.
What is the P/E ratio for Avanos Medical stock?
The price to earnings (P/E) ratio for Avanos Medical (AVNS) stock is 0 as of November 13, 2025.
Does Avanos Medical stock pay dividends?
No, Avanos Medical (AVNS) stock does not pay dividends to its shareholders as of November 13, 2025.
When is the next Avanos Medical dividend payment date?
Avanos Medical (AVNS) stock does not pay dividends to its shareholders.
What is the beta indicator for Avanos Medical?
Avanos Medical (AVNS) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.